Neshima
Neshima Medical aims to revolutionize respiratory medicine with its innovative Liquid Foam Therapy - LiFT™. The company develops paradigm-shifting technology to deliver therapeutics directly to the lungs, targeting unmet clinical needs such as pneumonia, mucus obstruction, asthma, and potentially lung regeneration for COPD patients. Their approach allows for high-concentration drug delivery beyond mucus obstructions, promising improved treatment efficacy and patient outcomes.
Industries
health-care
manufacturing
medical
pharmaceutical
Nr. of Employees
small (1-50)
Products
Intratracheal liquid-foam pulmonary delivery system
A platform combining foam-based formulations and an administration system to deliver therapeutics directly into the lungs for treatment of respiratory infections and other pulmonary indications.
Intratracheal liquid-foam pulmonary delivery system
A platform combining foam-based formulations and an administration system to deliver therapeutics directly into the lungs for treatment of respiratory infections and other pulmonary indications.
Expertise Areas
- Pulmonary drug delivery
- Foam formulation engineering
- Preclinical respiratory testing (ex vivo and in vitro)
- Therapeutic development for mechanically ventilated patients
Key Technologies
- Liquid-foam pulmonary delivery
- Shear-thinning foam formulations
- Intratracheal instillation techniques
- Ex vivo porcine lung models